CD36 and neoplasm: Several preclinical studies have demonstrated the efficacy of targeting fatty acid transporters such as fatty acid translocase, CD36, and fatty acid binding protein 4 (FABP4) in reducing tumor growth in various cancer types [102,143,144,145].